At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Valsartan on Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
In Brief
A Phase 3 clinical trial evaluating sacubitril/valsartan, valsartan, and 2 other interventions for Heart Failure With Preserved Ejection Fraction (HFpEF). Completed, enrolled 467 participants across 97 sites in 2 countries.
Detailed Summary
The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days post-decompensation.
Study Details
Timeline
Interventions
Sacubitril/valsartan (LCZ696) was available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily
Valsartan was available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily
Sacubitril/valsartan (LCZ696) matching placebo was available as tablet form to be taken orally, twice daily
Valsartan matching placebo was available as tablet form to be taken orally, twice daily